Business
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents
About this update from Fibrobiologics, Inc.
[{"type":"text","content":"HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (\"FibroBiologics\"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the development of a novel artificial thymus organoid that can restore immune function in a severe combined immunodeficiency (SCID) mouse model. The organoid, composed of fibroblasts and thymus derived cells, is capable of generating mature and diverse T cells, including CD4, CD8, and regulatory T cells, in vitro and in vivo. FibroBiologics intends to develop this technology as a subcutaneous injection of an allogeneic fibroblast-based organoid to restore thymus function lost due to age-related natural thymus involution, and for a rapid restoration of the immune system in patients who have gone through chemotherapy. \"This early research demonstrates the versatility and potential of fibroblasts and fibroblast-derived materials for regenerative medicine and immunotherapy,\" said Hamid Khoja, Ph.D., Chief Scientific Officer. \"Immune system dysregulation is the major cause of chronic inflammation, chronic diseases, and age-related immune senescence attributed to higher rates of cancer, autoimmune disorder, infection rate, and reduced response to vaccination in the elderly. We look forward to advancing this technology through further research efforts and to offer a new potential treatment for restoring thymus function and enabling a longer and healthier life.\" \"We are very encouraged with the results of our experimental studies in improving human longevity that demonstrate the feasibility of restoring thymus functionality with our artificial thymus organoid technology,\" said Pete O’Heeron, Founder and Chief Executive Officer. \"We believe that this technology has the potential to revolutionize the field of immunotherapy and provide a safe and effective alternative to stem cell transplantation.\" For more information, please visit FibroBiologics' website or email FibroBiologics at: [email protected]. Cautionary Statement Regarding Forward-Looking Statements This communication contains \"forward-looking statements\" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking sta...